GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » EBIT per Share

Transgene (XPAR:TNG) EBIT per Share : €-0.22 (TTM As of Jun. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Transgene EBIT per Share?

Transgene's EBIT per Share for the six months ended in Jun. 2024 was €-0.16. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.22.

During the past 3 years, the average EBIT per Share Growth Rate was 0.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was 6.30% per year. During the past 10 years, the average EBIT per Share Growth Rate was 13.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Transgene's EBIT per Share or its related term are showing as below:

XPAR:TNG' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -49.4   Med: 13.6   Max: 44.2
Current: 0.6

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Transgene was 44.20% per year. The lowest was -49.40% per year. And the median was 13.60% per year.

XPAR:TNG's 3-Year EBIT Growth Rate is ranked worse than
53.38% of 1257 companies
in the Biotechnology industry
Industry Median: 3.2 vs XPAR:TNG: 0.60

Transgene's EBIT for the six months ended in Jun. 2024 was €-15.94 Mil.


Transgene EBIT per Share Historical Data

The historical data trend for Transgene's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene EBIT per Share Chart

Transgene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 -0.19 -0.21 -0.32 -0.22

Transgene Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.17 -0.16 -0.06 -0.16

Transgene EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Transgene's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-22.16/100.590
=-0.22

Transgene's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

EBIT per Share(Q: Jun. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-15.943/100.957
=-0.16

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Transgene  (XPAR:TNG) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Transgene EBIT per Share Related Terms

Thank you for viewing the detailed overview of Transgene's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Transgene Business Description

Traded in Other Exchanges
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, FRA, 67400
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.

Transgene Headlines

No Headlines